| Market Cap | $5.87B+26.6% |
| Revenue (ttm) | $570.00K |
| Net Income | -$413.61M |
| EPS | -$3.23 |
| Shares Out | 122.00M |
| PE Ratio | n/a |
| Forward PE | -20.08 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,076,204 |
| Open | $49.63 |
| Previous Close | $50.37 |
| Day's Range | $47.94 - $52.17 |
| 52-Week Range | $38.69 - $61.76 |
| Beta | 0.79 |
| Analysts | Strong Buy |
| Price Target | $70.06(+45.57%) |
| Earnings Date | Nov 10, 2026 |
About SRRK
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Scholar Rock Holding Corp Stock Analysis — InsiderScore
Scholar Rock Holding Corp scored higher than 28% of companies evaluated by InsiderBuying, and ranked 58th out of 103 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Scholar Rock Holding Corp bought $12.00 million of stock across 6 purchases in the last 90 days, the largest of them $4.08 million.
The average purchase added about 6% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
12 firms rating SRRK in the last 3 months, one vote each. Issuer-paid research is not counted.
$SRRK stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in SRRK holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SRRK's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SRRK Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SRRK patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SRRK from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from SRRK’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 revenue beats and narrowing losses offset by pre-bell share decline; mixed but operationally constructive news around iSemble launch.
Recent Insider Activity
Insider Score Trend Over Time
-9.0 since Oct 30Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| IBRN | iShares Neuroscience and Healthcare ETF | 3.65% |
| MNTL | Tema Neuroscience And Mental Health ETF | 1.71% |
| TDNA | T. Rowe Price Biotech ETF | 1.58% |
| GURU | Global X - Guru Index ETF | 1.25% |
| XBI | State Street SPDR S&P Biotech ETF | 0.80% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.78% |
| SGRW | Harbor Active Small Cap Growth ETF (SGRW) | 0.75% |
| PCSG | Polen 5Perspectives Small-Mid Growth ETF | 0.58% |
| MMSC | First Trust Multi-Manager Small Cap Opportunities ETF | 0.50% |
| HRTS | Tema Heart & Health ETF | 0.46% |
| ACSG | American Century Small Cap Growth Insights ETF | 0.45% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.34% |
Weight is the stock’s share of each fund’s holdings.
